Brokerages predict that Novartis AG (NYSE:NVS) will post earnings per share (EPS) of $1.24 for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Novartis’ earnings. The lowest EPS estimate is $1.20 and the highest is $1.28. Novartis reported earnings per share of $1.28 during the same quarter last year, which would suggest a negative year over year growth rate of 3.1%. The company is expected to report its next quarterly earnings report on Thursday, April 18th.
According to Zacks, analysts expect that Novartis will report full-year earnings of $5.43 per share for the current financial year, with EPS estimates ranging from $5.22 to $5.60. For the next year, analysts anticipate that the firm will report earnings of $6.01 per share, with EPS estimates ranging from $5.73 to $6.25. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Novartis.
Novartis (NYSE:NVS) last posted its quarterly earnings results on Wednesday, January 30th. The company reported $1.24 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.33 by ($0.09). The business had revenue of $13.27 billion during the quarter, compared to analyst estimates of $13.33 billion. Novartis had a return on equity of 15.66% and a net margin of 24.30%. The business’s revenue was up 2.7% on a year-over-year basis. During the same quarter last year, the firm earned $1.21 EPS.
Hedge funds have recently modified their holdings of the stock. Raymond James Trust N.A. grew its stake in shares of Novartis by 41.8% during the third quarter. Raymond James Trust N.A. now owns 47,271 shares of the company’s stock worth $4,072,000 after purchasing an additional 13,938 shares in the last quarter. Bourgeon Capital Management LLC grew its stake in shares of Novartis by 5.3% during the third quarter. Bourgeon Capital Management LLC now owns 69,463 shares of the company’s stock worth $5,985,000 after purchasing an additional 3,490 shares in the last quarter. Ipswich Investment Management Co. Inc. grew its stake in shares of Novartis by 17.0% during the fourth quarter. Ipswich Investment Management Co. Inc. now owns 29,463 shares of the company’s stock worth $2,528,000 after purchasing an additional 4,278 shares in the last quarter. Patton Albertson Miller Group LLC acquired a new position in shares of Novartis during the third quarter worth $211,000. Finally, Blair William & Co. IL grew its stake in shares of Novartis by 0.8% during the third quarter. Blair William & Co. IL now owns 174,778 shares of the company’s stock worth $15,059,000 after purchasing an additional 1,463 shares in the last quarter. Hedge funds and other institutional investors own 10.99% of the company’s stock.
NYSE:NVS opened at $88.85 on Wednesday. The firm has a market capitalization of $204.67 billion, a price-to-earnings ratio of 17.46, a price-to-earnings-growth ratio of 1.93 and a beta of 0.69. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.20 and a quick ratio of 0.97. Novartis has a 52 week low of $72.30 and a 52 week high of $92.39.
The company also recently announced an annual dividend, which will be paid on Wednesday, March 13th. Investors of record on Tuesday, March 5th will be paid a dividend of $2.8646 per share. The ex-dividend date of this dividend is Monday, March 4th. This represents a dividend yield of 3.27%. This is an increase from Novartis’s previous annual dividend of $2.33. Novartis’s payout ratio is presently 37.52%.
Novartis Company Profile
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.